PURPOSE: To investigate therapeutic outcome of dose escalation ≥ 80 Gy in nonresected non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: 124 consecutive patients with histologically/cytologically proven NSCLC were enrolled. Tumor stage I, II, IIIA, and IIIB was diagnosed in 30, eight, 39, and 47 patients, respectively. 38 patients (31%) had weight loss > 5% during the 3 months before diagnosis. A median dose of 88.2 Gy (range 80.0-96.0 Gy), 69.3 Gy (63.0-88.0 Gy) and 56.7 Gy was applied to primary lesions, involved lymph nodes, and elective nodes (within a region of about 6 cm cranial to macroscopically involved nodes), respectively. Daily fractional ICRU doses of 2.0-2.2 Gy were delivered by the conformal target-splitting technique. 58 patients (47%) received induction chemotherapy, in median two cycles prior to radiotherapy. RESULTS: Median follow-up time of all patients was 19 months, of patients alive 72.4 months (69-121 months). The cumulative actual overall survival rate at 2 and 5 years amounts to 39% and 11.3%, respectively, resulting in a median overall survival time of 19.6 months. According to stages I, II, IIIA, and IIIB, the median overall survival times are 31.8, 31.4, 19.0, and 14.5 months, respectively. The locoregional tumor control rate at 2 years is 49%. Apart from one treatment-related death (pneumonitis), acute toxicity according to EORTC/RTOG scores was moderate: lung grade 2 (n = 7), grade 3 (n = 3); esophagus grade 1 (n = 11); heart grade 3 (n = 1, pericarditis). No late toxicity grade > 1 has been observed. CONCLUSION: Sequential, conventionally fractionated high-dose radiotherapy by conformal target splitting is well tolerated. The results for survival and locoregional tumor control seem to at least equalize the outcome of simultaneous chemoradiation approaches, which, at present, are considered "state of the art" for patients with nonresected NSCLC. A higher potential of radiation therapy might be reached by accelerated fractionation regimens.
PURPOSE: To investigate therapeutic outcome of dose escalation ≥ 80 Gy in nonresected non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: 124 consecutive patients with histologically/cytologically proven NSCLC were enrolled. Tumor stage I, II, IIIA, and IIIB was diagnosed in 30, eight, 39, and 47 patients, respectively. 38 patients (31%) had weight loss > 5% during the 3 months before diagnosis. A median dose of 88.2 Gy (range 80.0-96.0 Gy), 69.3 Gy (63.0-88.0 Gy) and 56.7 Gy was applied to primary lesions, involved lymph nodes, and elective nodes (within a region of about 6 cm cranial to macroscopically involved nodes), respectively. Daily fractional ICRU doses of 2.0-2.2 Gy were delivered by the conformal target-splitting technique. 58 patients (47%) received induction chemotherapy, in median two cycles prior to radiotherapy. RESULTS: Median follow-up time of all patients was 19 months, of patients alive 72.4 months (69-121 months). The cumulative actual overall survival rate at 2 and 5 years amounts to 39% and 11.3%, respectively, resulting in a median overall survival time of 19.6 months. According to stages I, II, IIIA, and IIIB, the median overall survival times are 31.8, 31.4, 19.0, and 14.5 months, respectively. The locoregional tumor control rate at 2 years is 49%. Apart from one treatment-related death (pneumonitis), acute toxicity according to EORTC/RTOG scores was moderate: lung grade 2 (n = 7), grade 3 (n = 3); esophagus grade 1 (n = 11); heart grade 3 (n = 1, pericarditis). No late toxicity grade > 1 has been observed. CONCLUSION: Sequential, conventionally fractionated high-dose radiotherapy by conformal target splitting is well tolerated. The results for survival and locoregional tumor control seem to at least equalize the outcome of simultaneous chemoradiation approaches, which, at present, are considered "state of the art" for patients with nonresected NSCLC. A higher potential of radiation therapy might be reached by accelerated fractionation regimens.
Authors: Mitchell Machtay; Chuanchieh Hsu; Ritsuko Komaki; William T Sause; R Suzanne Swann; Corey J Langer; Roger W Byhardt; Walter J Curran Journal: Int J Radiat Oncol Biol Phys Date: 2005-05-31 Impact factor: 7.038
Authors: Jeffrey Bradley; Mary V Graham; Kathryn Winter; James A Purdy; Ritsuko Komaki; Wilson H Roa; Janice K Ryu; Walter Bosch; Bahman Emami Journal: Int J Radiat Oncol Biol Phys Date: 2005-02-01 Impact factor: 7.038
Authors: K Furuse; M Fukuoka; M Kawahara; H Nishikawa; Y Takada; S Kudoh; N Katagami; Y Ariyoshi Journal: J Clin Oncol Date: 1999-09 Impact factor: 44.544
Authors: J D Cox; T F Pajak; S Asbell; A H Russell; J Pederson; R W Byhardt; B Emami; M Roach Journal: Int J Radiat Oncol Biol Phys Date: 1993-10-20 Impact factor: 7.038
Authors: Ramesh Rengan; Kenneth E Rosenzweig; Ennapadam Venkatraman; Lawrence A Koutcher; Jana L Fox; Reena Nayak; Howard Amols; Ellen Yorke; Andrew Jackson; C Clifton Ling; Steven A Leibel Journal: Int J Radiat Oncol Biol Phys Date: 2004-11-01 Impact factor: 7.038
Authors: D De Ruysscher; J Van Meerbeeck; K Vandecasteele; C Oberije; M Pijls; A M C Dingemans; B Reymen; A van Baardwijk; R Wanders; G Lammering; P Lambin; W De Neve Journal: Strahlenther Onkol Date: 2012-04-29 Impact factor: 3.621
Authors: Adrian Staab; Markus Fleischer; Juergen Loeffler; Harun M Said; Astrid Katzer; Christian Plathow; Herrmann Einsele; Michael Flentje; Dirk Vordermark Journal: Strahlenther Onkol Date: 2011-03-25 Impact factor: 3.621
Authors: V Duncker-Rohr; U Nestle; F Momm; V Prokic; F Heinemann; M Mix; J Reusch; M-B Messmer; N Marschner; C F Waller; W A Weber; A-L Grosu Journal: Strahlenther Onkol Date: 2013-01 Impact factor: 3.621
Authors: Karl Wurstbauer; Heinz Deutschmann; Karin Dagn; Peter Kopp; Franz Zehentmayr; Bernd Lamprecht; Peter Porsch; Birgit Wegleitner; Michael Studnicka; Felix Sedlmayer Journal: Radiat Oncol Date: 2013-03-05 Impact factor: 3.481